Why the study?
Does the choice of direct oral anticoagulant (rivaroxaban, apixaban, or edoxaban) affect recurrence, thrombus regression, and safety in patients with venous thromboembolism?
Does the choice of direct oral anticoagulant (rivaroxaban, apixaban, or edoxaban) affect recurrence, thrombus regression, and safety in patients with venous thromboembolism?
Rivaroxaban, apixaban, and edoxaban demonstrated comparable efficacy and safety for VTE treatment in real-world practice, even when tailored to patient characteristics such as age and renal function.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Nakai et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: